Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551291 | 0.89 | MEN1 (0.47) | FFAR2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1550616 | 0.87 | FFAR2 (0.37) | FFAR2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1987375 | 0.87 | GRM5 (0.47) | FFAR2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1989636 | 0.86 | SMN1; SMN2 (0.42) | FFAR2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1989363 | 0.85 | KMT2A (0.40) | FFAR2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1987986 | 0.85 | FFAR2 (0.45) | FFAR2MEN1KMT2AALDH1A1GCK | |
| SCHEMBL1997351 | 0.85 | NPC1 (0.41) | LMNAMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1993913 | 0.84 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1990276 | 0.83 | GRM5 (0.50) | KMT2A | |
| SCHEMBL1989733 | 0.83 | SIRT2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | FFAR2 3135/4885LMNA 2384/4885MEN1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.